Inhaler Propellants for Asthma
Recruiting in Palo Alto (17 mi)
Age: 18 - 65
Sex: Any
Travel: May Be Covered
Time Reimbursement: Varies
Trial Phase: Phase 1
Recruiting
Sponsor: GlaxoSmithKline
No Placebo Group
Trial Summary
What is the purpose of this trial?
The purpose of the study is to assess the propellants,1 - Difluoroethane \[HFA-152a\] (Test) and 1,1,1,2-Tetrafluoroethane \[HFA-134a\] (Reference) for their potential to cause the airways to tighten when delivered through pressurized metered dose inhalers (pMDI). The rationale for this study is to develop a low carbon footprint alternative propellant, HFA-152a, which will have a lower impact on global warming.
Research Team
Eligibility Criteria
This trial is for adults aged 18-45 with mild asthma, diagnosed at least 6 months ago. They must have stable asthma without severe flare-ups in the past 6 months and not be on certain medications or therapies. Women of childbearing age should meet pregnancy prevention criteria.Inclusion Criteria
ACQ-6 score <1.5 at screening and Day -1
I am either a man or a woman, regardless of my ability to have children.
I am not pregnant and follow the required birth control measures.
See 7 more
Exclusion Criteria
I have had severe or uncontrolled asthma.
I am currently undergoing de-sensitization therapy.
My medication doses have not changed recently.
See 5 more
Treatment Details
Interventions
- HFA-134A propellant (Propellant)
- HFA-152A propellant (Propellant)
Trial OverviewThe study compares two propellants used in inhalers: HFA-152a (test) and HFA-134a (reference). It aims to see if they cause airway tightening when used by people with mild asthma, looking for a greener option with less impact on global warming.
Participant Groups
2Treatment groups
Experimental Treatment
Group I: HFA-152A propellant followed by HFA-134A propellantExperimental Treatment2 Interventions
Group II: HFA-134A propellant followed by HFA-152A propellantExperimental Treatment2 Interventions
Find a Clinic Near You
Who Is Running the Clinical Trial?
GlaxoSmithKline
Lead Sponsor
Trials
4,834
Recruited
8,389,000+
Headquarters
London, UK
Known For
Vaccines & Medicines
Top Products
**Advair (salmeterol, fluticasone propionate)**, **Shingrix (shingles vaccine)**, **Augmentin (amoxicillin/clavulanate potassium)**, **Ventolin (salbutamol sulfate)
Dame Emma Walmsley
GlaxoSmithKline
Chief Executive Officer since 2017
MA in Classics and Modern Languages from Oxford University
Dr. Hal Barron
GlaxoSmithKline
Chief Medical Officer since 2018
MD from Harvard Medical School